Mentz RJ, DeVore AD, Tasissa G, et al. - Since ivabradine initiation after acute heart failure (HF) has had limited assessment, and there exist few randomized data in US patients, so, researchers addressed predischarge ivabradine start in stabilized acute HF patients enrolled in the PredischaRge initiation of Ivabradine in the ManagEment of Heart Failure (PRIME-HF) study, which represents an investigator-initiated, randomized, open-label study. Predischarge start of ivabradine vs usual care was assessed. The proportion of patients receiving ivabradine at 180 days was considered as the primary endpoint. Among stabilized HF patients, an increase in ivabradine use at 180 days and lowered heart rates without decrease in β-blockers or increase in adverse events were reported as the consequences of initiating ivabradine before discharge.